Rhythm Pharmaceuticals

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for patients with rare genetic disorders of obesity. Our mission is to develop innovative therapies that address the unmet medical needs of individuals suffering from these conditions, ultimately improving their quality of life.

At Rhythm, we focus on leveraging our deep understanding of the biology of obesity and its related disorders. Our research and development efforts are centred around discovering and advancing novel therapeutics that target the underlying mechanisms of these diseases. We believe in a patient-centric approach, ensuring that our solutions are tailored to meet the specific needs of those we serve.

Our flagship product, setmelanotide, has shown promising results in clinical trials, demonstrating significant efficacy in patients with specific genetic mutations. This breakthrough therapy represents a significant advancement in the management of obesity caused by genetic factors.

We are committed to fostering a culture of innovation and collaboration, working closely with healthcare professionals, researchers, and patient advocacy groups. By engaging with the community, we aim to raise awareness about rare genetic disorders and advocate for better treatment options.

As we continue to grow, our vision remains clear: to be a leader in the field of rare genetic disorders of obesity, driving scientific advancements and delivering impactful therapies to patients worldwide.

• Core Values: Innovation, Integrity, Collaboration, Patient-Centricity
• Headquarters: Based in the UK, we are strategically positioned to engage with global markets.
• Future Goals: Expand our pipeline of therapies and enhance our commitment to patient advocacy.